Here are six things to know:
1. The company’s novel biosynthetic bone graft extender and substitute InQu are designed to promote bone formation in orthopedic procedures and spinal fusions.
2. Study results published in Frontiers in Surgery demonstrated that InQu supports significantly faster spinal fusion compared to beta-tricalcium phosphate and is associated with higher overall fusion rates at 12-months.
3. The company’s Influx trabecular bone graft is a natural material designed to provide osteoinductivity and promote cell ingrowth.
4. Isto Biologics also manufactures the Magellan autologous platelet separator, Lightning aspiration needle and CellPoint concentrate bone marrow aspirate system.
5. The company provides blood management services.
6. In 2017, Isto Biologics acquired Progenicare, a medical sales and service company.
More articles on biologics:
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Vericel appoints CMO: 3 details
17 key players in the global spine biologics market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
